Diagnostics

A powerful new genomic tool is turning genetic doubt into diagnostic certainty, helping thousands of patients understand their true hereditary cancer risk.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Organon expands its Women's Health Accelerator to META, aiming to close health gaps and unlock a potential £1 trillion economic boost through digital innovation.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

A new partnership brings acute end-of-life care into a residential setting, allowing Austin seniors to receive critical support without leaving home.

A new analysis of malpractice claims reveals the top drivers of patient harm in cardiology, offering critical insights to save lives and protect careers.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

Quanterix has submitted a multi-biomarker blood test to the FDA, a move that could revolutionize early Alzheimer's diagnosis and patient care.

A new data-driven wellness program in Ontario is dramatically reducing cancer risk for firefighters, offering a blueprint for saving lives and city funds.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A new report reveals a major shift in hospital spending, with tech and infrastructure costs now rising faster than drugs for the first time in a decade.

National imaging giant RadNet has acquired Northwest Radiology's six centers, marking its entry into Indiana and signaling a major shift for the Midwest market.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

A C$20M investment validates Corus's unique doctor-led model, fueling a major expansion across the booming North American orthodontic market.

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

At MD&M West 2026, Boyd showcases how materials science and regulatory expertise are the unsung heroes behind the next wave of medical wearables.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

With backing from a top hospital, VolitionRx seeks reimbursement for its Nu.Q® blood test, aiming to transform lung cancer care in France and beyond.